These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12462152)

  • 21. Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.
    Friedler A; Blumenzweig I; Baraz L; Steinitz M; Kotler M; Gilon C
    J Mol Biol; 1999 Mar; 287(1):93-101. PubMed ID: 10074409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adaptive inhibitors of the HIV-1 protease.
    Ohtaka H; Freire E
    Prog Biophys Mol Biol; 2005 Jun; 88(2):193-208. PubMed ID: 15572155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.
    Hidaka K; Kimura T; Abdel-Rahman HM; Nguyen JT; McDaniel KF; Kohlbrenner WE; Molla A; Adachi M; Tamada T; Kuroki R; Katsuki N; Tanaka Y; Matsumoto H; Wang J; Hayashi Y; Kempf DJ; Kiso Y
    J Med Chem; 2009 Dec; 52(23):7604-17. PubMed ID: 19954246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural analyses of 2015-updated drug-resistant mutations in HIV-1 protease: an implication of protease inhibitor cross-resistance.
    Su CT; Ling WL; Lua WH; Haw YX; Gan SK
    BMC Bioinformatics; 2016 Dec; 17(Suppl 19):500. PubMed ID: 28155724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
    Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezácová P; Brynda J; Pokorná J; Plesek J; Grüner B; Grantz Sasková K; Václavíková J; Král V; Konvalinka J
    J Med Chem; 2008 Aug; 51(15):4839-43. PubMed ID: 18598016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of a set of HIV-1 protease inhibitors using binding kinetics data from a biosensor-based screen.
    Hämäläinen MD; Markgren PO; Schaal W; Karlén A; Classon B; Vrang L; Samuelsson B; Hallberg A; Danielson UH
    J Biomol Screen; 2000 Oct; 5(5):353-60. PubMed ID: 11080694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.
    Ohtaka H; Velázquez-Campoy A; Xie D; Freire E
    Protein Sci; 2002 Aug; 11(8):1908-16. PubMed ID: 12142445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A kinetic model for comparing proteolytic processing activity and inhibitor resistance potential of mutant HIV-1 proteases.
    Tang J; Hartsuck JA
    FEBS Lett; 1995 Jun; 367(2):112-6. PubMed ID: 7796905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dimerization inhibitors of HIV-1 reverse transcriptase, protease and integrase: a single mode of inhibition for the three HIV enzymes?
    Camarasa MJ; Velázquez S; San-Félix A; Pérez-Pérez MJ; Gago F
    Antiviral Res; 2006 Sep; 71(2-3):260-7. PubMed ID: 16872687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV protease inhibition: limited recent progress and advances in understanding current pitfalls.
    Rodríguez-Barrios F; Gago F
    Curr Top Med Chem; 2004; 4(9):991-1007. PubMed ID: 15134553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sidechain-linked inhibitors of HIV-1 protease dimerization.
    Bowman MJ; Chmielewski J
    Bioorg Med Chem; 2009 Feb; 17(3):967-76. PubMed ID: 18337105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach.
    Jenwitheesuk E; Samudrala R
    Antivir Ther; 2005; 10(1):157-66. PubMed ID: 15751773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands.
    Qiu X; Zhao GD; Tang LQ; Liu ZP
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2465-8. PubMed ID: 24767846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The HIV-1 protease as enzyme and substrate: mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties.
    Mildner AM; Rothrock DJ; Leone JW; Bannow CA; Lull JM; Reardon IM; Sarcich JL; Howe WJ; Tomich CS; Smith CW
    Biochemistry; 1994 Aug; 33(32):9405-13. PubMed ID: 8068616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate -- interactions with frequently occurring glutamic acid residue at P2' position of substrates.
    Weber IT; Wu J; Adomat J; Harrison RW; Kimmel AR; Wondrak EM; Louis JM
    Eur J Biochem; 1997 Oct; 249(2):523-30. PubMed ID: 9370363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design of tight-binding human immunodeficiency virus type 1 protease inhibitors.
    Vacca JP
    Methods Enzymol; 1994; 241():311-34. PubMed ID: 7854186
    [No Abstract]   [Full Text] [Related]  

  • 37. Synergistic binding of inhibitors to the protease from HIV type 1.
    Asante-Appiah E; Chan WW
    Biochem J; 1996 Apr; 315 ( Pt 1)(Pt 1):113-7. PubMed ID: 8670094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
    Muzammil S; Ross P; Freire E
    Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease.
    Dauber DS; Ziermann R; Parkin N; Maly DJ; Mahrus S; Harris JL; Ellman JA; Petropoulos C; Craik CS
    J Virol; 2002 Feb; 76(3):1359-68. PubMed ID: 11773410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV protease: enzyme function and drug resistance.
    Gulnik S; Erickson JW; Xie D
    Vitam Horm; 2000; 58():213-56. PubMed ID: 10668400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.